© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Lumefantrine traces its roots to the critical decades of antimalarial drug discovery, springing from the scientific fervor that followed the widespread resistance to chloroquine in the late twentieth century. Researchers in China, especially across dedicated state-backed pharmaceutical teams, sought new answers amid a backdrop of increasing global malaria deaths. The big milestone came in the late 1970s, as investigators worked with the framework of aryl amino alcohols, closely related in many respects to other drugs like mefloquine. Instead of sticking with older structures, the new molecule harnessed a longer side chain, pushing for enhanced activity against Plasmodium falciparum, the deadliest malaria parasite. Taking cues from both European and Asian research, the final form of lumefantrine landed in clinics paired with artemether, setting a new standard in artemisinin-based combination therapies.
As a therapeutic agent born from necessity, lumefantrine exhibits robust action against blood-stage malaria parasites. In practice, lumefantrine almost never stands alone; its trusted partner is artemether, and together they carve down parasite loads in patients at a speed unmatched by their forerunners. Pharmaceutical firms produce this compound as crystalline yellow powder, pressing it into scored tablets for easy dosing. Major brands include Coartem, and many generics follow suit. Healthcare workers prize this regimen for its rapid effect, offering a real shot at full parasite clearance and much-needed symptom relief in children and adults. Deeply ingrained into the World Health Organization’s guidelines, this power couple fuels malaria campaigns from rural clinics to urban hospitals across Africa, Asia, and Latin America.
Lumefantrine appears as a yellow, crystalline solid, carrying a molecular formula of C30H32Cl3NO. Its melting point floats around 130°C, and it carries poor water solubility, a trait that sets certain demands during formulation. The molecule counts three chlorine atoms, infusing the structure with stability and contributing to its long-lasting effect in human blood. In chemical terms, it belongs to the aryl amino alcohol family, where the arrangement of aromatic rings and an alcohol side chain creates strong antiplasmodial activity. NMR and mass spectrometry confirm its structure, and infrared analysis verifies its purity batch after batch. The low solubility challenges scientists, pushing them to optimize tablet design so the drug absorbs efficiently in the digestive tract. Patient trials confirm that bioavailability climbs dramatically with fatty food, and dosing recommendations reflect this fact.
Drug labels list lumefantrine as the key partner to artemether, usually found in a fixed-ratio combination tablet. Dosage strengths often reach 120 mg of lumefantrine matched to 20 mg artemether per tablet. Regulatory filings demand clear labeling of strength, manufacturer, expiry, batch number, and storage recommendations—since moisture and high temperatures threaten the integrity of the tablets. Professional packaging comes tamper-proof with anti-counterfeit measures. Specifications document strict limits on impurities, as outlined by ICH guidelines, and stipulate microbiological purity and elemental impurity thresholds. Pharmacopoeia monographs flesh out detailed tests for dissolution, assay by HPLC, and identification using TLC and spectrometry. Tablets always include instructions for taking with food, boosting absorption and clinical success.
Industrial production of lumefantrine starts with a multi-step organic synthesis, drawing from common aromatic raw materials. Chemists usually kick off the process by condensing a substituted benzophenone with a Grignard reagent, shaping the core carbon skeleton. Linear chain extension and halogenation steps follow, using controlled addition of chlorinating agents and reduction protocols. The most delicate phases cater to chiral centers and final purification, achieved through crystallization and solvent exchange that rinse away unreacted residues. Most factories alternate between batch and continuous methods, favoring the approach that best fits quality and volume demands. Final drying and milling deliver fine powder for tableting. Environmental safeguards—solvent recovery systems, dedicated waste neutralizing units—offer crucial checks, reflecting growing scrutiny around chemical manufacturing.
Chemists have explored several modifications to lumefantrine, often adjusting the chlorine content and altering side chains to probe pharmacological boundaries. Debates continue around which substituents improve binding to parasite heme targets or help dodge resistance. Brominated analogs, methyl side-chain swaps, and tweaks to the secondary alcohol have appeared in patent filings, but few challenge the parent compound in clinical tests. Stability and bioavailability checks round out the most promising changes. Intermediates from the main synthetic route offer themselves as scaffolds, enabling vertical integration in supply chains and cost-effective scale-up.
Lumefantrine pops up under several names in literature and commerce. Its development literature cites "benflumetol" as a key synonym, a term still used through some generic channels. Coartem stands as the flagship branded product, and national formularies often list both artemether and lumefantrine prominently. Patent filings and API catalogs tag the compound under a variety of internal reference numbers, but at the pharmacy counter, medical teams stick to “artemether-lumefantrine” for clear communication with patients.
Every batch deployed to the field passes through elaborate checks for potency, purity, and safety. Manufacturing standards track the full range of ICH Q7 and cGMP processes. Analytical labs run validated test methods to rule out carcinogenic or mutagenic impurities. Storage rules keep lumefantrine tablets below 30°C and away from moisture. Staff across these supply chains handle powders with gloves, fitted masks, and eye shields, limiting exposure and avoiding cross-contamination. The drug itself sits on the essential medicines list, but prescribers stay cautious—pregnant women, infants below 5 kg, and folks with rare enzyme deficiencies need targeted assessment before therapy starts. Regulatory audits often inspect documentation, recalling that breakdowns in discipline can lead to serious consequences for communities counting on reliable malaria drugs.
Lumefantrine worked its way into malaria programs as resistance to older therapies threatened millions. Medical agencies put it at the front line for uncomplicated Plasmodium falciparum infections, a role confirmed through randomized trials spanning more than forty countries. Doctors in districts plagued by seasonal outbreaks find this compound invaluable, especially in regions where local strains shake off chloroquine and sulfadoxine-pyrimethamine with ease. Its use meshes closely with rapid diagnostic tests, filling the treatment window before complications take hold. Urban clinics, remote health posts, refugee field hospitals—each deploys the drug where fevers spark waves of sickness after heavy rains or mass migrations. Special protocols guide use among children, pregnant women (in later trimesters), and travelers, aiming for full recovery without relapse. Beyond curative care, this combination plays a part in mass drug administration and intermittent preventive campaigns as endorsed by global health leaders.
Scientists keep tinkering with both the chemistry and clinical use of lumefantrine. Research focuses on smoothing out bioavailability, extending shelf life in steamy climates, and lowering production costs for low-resource settings. Some teams have experimented with co-formulating other antimalarial partners, hoping to break through early resistance signals while simplifying dosing. Field trials gather pharmacovigilance data to catch rare side effects, especially as millions more take the drug every year. Geneticists and epidemiologists mine databases for mutations linked to reduced lumefantrine response, sounding early warnings that could provoke reformulation or regime changes. Meanwhile, drug developers create pediatric syrup formulations, dispersible tablets, and patient-friendly calibrations to tackle logistical snags in rural and mobile delivery settings.
Lumefantrine’s toxicity profile draws from careful testing across animal models, cell assays, and large-scale patient registries. Most evidence points to a wide safety margin at therapeutic doses, but clinical teams document rare cardiac effects—QT interval prolongation, in particular—when overdosed or mixed with certain other drugs. Labs keep an eye on hepatic profiles, recognizing that impaired metabolism in some patients could heighten risk. Data from multi-country observational cohorts reassure most regulators, but ongoing studies dig into signals of cross-reactivity and long-term exposure in vulnerable groups. National authorities set strict pharmacovigilance reporting and batch release criteria in light of these findings, sometimes tweaking dose guidelines to keep pace with fresh evidence.
Even in an age full of molecular screens and next-gen chemistries, lumefantrine won’t fade any time soon. Plasmodium strains drift and mutate, but the combination with artemether buys frontline doctors valuable time. The main challenge lies in slipping bioavailability and the creeping signs of partial resistance in certain zones of Southeast Asia. To keep pace, firms ramp up research into improved formulations—lipid suspensions, solid dispersions, and nano-particulate blends top the list. Efforts to broaden the drug’s reach appear in public health policy, aiming for wider preventive strategies in mass campaigns. Scientists listen to genetic markers in the parasite, poised to tweak dosage or pivot drugs before resistance overruns another generation. The story of lumefantrine—born from crisis, cemented in practice, still pushing the boundary—reminds us that sturdy, time-tested chemistry can still change the world when backed by proper science and local dedication.
Malaria is not just a distant story for people living in many parts of Africa and Southeast Asia. It’s a regular battle. Lumefantrine, teamed up with artemether, delivers real hope in that fight. Malaria, caused by Plasmodium parasites passed through mosquito bites, can be life-threatening if left untreated. Lumefantrine steps in as an antimalarial, designed to clear out these parasites from the blood and help people get back on their feet.
This medicine isn’t something you take by itself. Doctors prescribe it as part of a combo pill with artemether. Each drug pulls its own weight: artemether starts killing off parasites quickly, lumefantrine sticks with the job to finish them off so they don’t come back. Decades ago, chloroquine and other drugs did the trick, but resistance became a real problem. Today, these combination therapies save countless lives each year in places where malaria is stubborn.
I’ve seen how malaria can sweep through families and communities, knocking people flat — especially young children and pregnant women who don’t have the tools to fight back. Without access to effective drugs, the odds stack up against them. The World Health Organization points to artemether-lumefantrine as one of the most reliable treatments for uncomplicated malaria caused by Plasmodium falciparum, the form most likely to kill. Timely treatment means fewer deaths, less time lost from work and school, and lower risk of severe illness. The combination pill also makes it easier for people to stick with the treatment — no need to keep track of multiple medications.
Reliable access to lumefantrine is not a guarantee in every rural clinic. Supply chain issues and cost can leave clinics short, especially during rainy seasons with big malaria spikes. Counterfeit drugs pose another big threat. The Partnership for Quality Medical Campaigns has flagged fake artemisinin combinations in handfuls of countries. These fakes don’t just waste money, they let the disease take hold and contribute to tougher, resistant parasites.
No drug keeps working forever if it stays the sole tool in the kit. Artemisinin resistance picks up in Southeast Asia — a warning sign for Africa. If resistance moves in, lumefantrine can’t clean up what artemether lets slip through. The world saw this happen before with older drugs. Fighting resistance calls for strong monitoring systems and smart drug policies. Doctors and health workers need updated local guidance on what still works, so people don’t get left behind when older treatments lose their power. Research and investment into new options, vaccines, and mosquito control help as backup lines of defense.
None of these medical breakthroughs matter if people can’t reach the clinic, afford the medicine, or don’t know why treatment matters. Governments and aid partners have pushed mobile clinics, education campaigns, and drug subsidy programs. Supporting local healthcare workers who know their communities and can spot outbreaks makes a direct difference. Strengthening supply chains, investing in diagnostics, and keeping quality control tight matter every step of the way. Malaria took far too many lives before; with lumefantrine, there is a fighting chance for families to live healthier lives and look towards the future.
Lumefantrine tackles the burden of malaria, usually paired with artemether. This combination remains a standard for people who face malaria infections in many parts of the world, including sub-Saharan Africa and parts of Asia. I recall visiting health clinics in Tanzania where this medicine was stacked high behind glass, always in demand after the rainy season. People ask for it by name because it brings relief after days of fever and chills.
Taking lumefantrine with food, especially foods containing fat, turns out to be a major factor in whether the medicine works or not. Doctors, pharmacists, and nurses, including those I’ve worked with, often tell patients to eat something small if they have nothing big available. A spoonful of oil, a bit of milk, even a little buttered bread does the trick. Lumefantrine dissolves better and enters the bloodstream more effectively in the presence of dietary fat. Skipping food with the dose cuts down how much medicine gets absorbed, which raises the risk of malaria sticking around longer or returning stronger.
Six doses over three days: easy to say, tough to follow if you’re running a fever or struggling with nausea. In real life, kids spit out doses, parents mix tablets with porridge, and people set alarms or wrap the blister packs in colored cloths as reminders. Missing or delaying doses hurts chance of recovery. The World Health Organization and local health agencies all stress, with good reason, the need to finish the full course—no matter how quickly the symptoms fade. In countries with weak health systems, incomplete treatment fuels the rise of resistant parasites, leading to longer, harder illness for whole communities.
Taking lumefantrine with alcohol, heart rhythm medicines, or certain antibiotics can trigger real trouble. The drug sits in the liver for processing, so adding extra strain can lead to side effects or drug interactions. Many malaria clinics now teach patients to report all medicines they’re already taking. Staff repeat this message in local languages, sometimes using stories or skits. People tend to remember what’s said with humor or music much longer than printed leaflets in a waiting room. This personal touch saves lives.
Pediatrics and pregnancy add a layer of complexity. Some children struggle with standard tablet doses and pregnant women face different safety considerations, especially in the first trimester. Nurses I’ve worked alongside measure doses by age or weight, sometimes crushing tablets and mixing with sweet drinks for kids. Each approach needs thought and care, with hands-on teaching when possible. More outreach, clear instructions, and community support solve many hurdles before they grow into crises.
Trust forms the bedrock of successful malaria treatment. Health workers, community elders, and families work together using clear, direct language to explain why lumefantrine has to be taken with food and finished on schedule. Mobile phones buzz with reminders, radio presenters share tips about malaria medicines, and schoolteachers keep an eye out for absent kids struggling at home with illness. Investing effort in patient education, translation, and support systems boosts the odds that treatment works for everyone, not just the lucky or well-informed.
Lumefantrine teams up with artemether in a widely used malaria treatment. Malaria remains a reality across parts of Asia, Africa, and South America, and this medication offers a lifeline for millions. Like every drug, Lumefantrine comes with its own set of trade-offs—side effects that sometimes catch people off guard. Knowing what to look out for is part of staying healthy, especially for travelers or residents in malaria-prone areas.
The most familiar side effects don’t leave anyone guessing. Stomach upset tops the list. Nausea, vomiting, and abdominal pain crop up for many users. Some folks compare it to a rough patch after a bad meal—mild discomfort, but still enough to slow a person down. Headaches don’t lag far behind. They can show up early in the course of treatment or persist for a few days, sometimes with a feeling of heaviness or pressure.
Dizziness makes an appearance too, especially as someone’s body adjusts to the drug. There’s a physical aspect—maybe a sense of lightheadedness or wooziness that reminds people to sit down and take it easy for a while.
Loss of appetite affects some users, leaving mealtimes less enjoyable. It sounds small, but when fighting malaria zaps energy, not having an appetite can slow recovery. Muscle or joint pains creep up in periodic waves, a low aching beat rather than sharp pain, but it still hangs around in the background of the day.
Sleep disturbances turn up in the discussion, too. It’s not everyone, but those who experience insomnia or strange dreams remember it. Some of those who have taken Lumefantrine say they woke up the next day feeling fuzzy, almost as if they hadn’t rested.
Studies have put numbers on these experiences. Research cited by the World Health Organization suggests up to 30% of patients on Lumefantrine report stomach and head symptoms. That figure isn’t minor. A study published in the journal Malaria Journal documented dizziness and appetite changes in 10–15% of cases. These are not rare outliers—real people in everyday settings deal with them. Children seem a bit more likely than adults to experience vomiting, based on systematic reviews comparing usage in young patients to adults.
Over the years, speaking to healthcare workers in malaria-endemic regions, I’ve seen how much daily practices help. Taking Lumefantrine with food reduces nausea for many. Splitting doses at steady intervals brings stomach issues under better control. People stay hydrated and rest, which lessens headaches and tiredness. For persistent or severe reactions, doctors recommend pausing and seeking out clinics for medical advice. For patients with heart issues, any unusual palpitations or chest pain gets immediate attention, since rare cardiac effects can occur.
Education means everything in these communities. Most side effects get managed well if people recognize them and don’t panic. Public health workers often help families understand what’s normal and when to check in with a nurse or doctor. Encouraging reporting of symptoms helps build safer strategies for long-term malaria control. In areas with limited clinics, simple steps—like posting side effect information at community gathering points or on clinic walls—give people a sense of control over their health journey with Lumefantrine.
Growing up in West Africa, I saw how much damage malaria causes, not just in children but also in pregnant women. A pregnant mother faces double the risk—not only for herself but also for her baby. Malaria can trigger miscarriage, preterm birth, stillbirth, or babies born too small. Treatment decisions aren’t trivial. They shape the outcomes for two people at once.
Lumefantrine, usually given with artemether, forms a combination medicine that’s become more common where malaria hits hardest. Many doctors trust artemether-lumefantrine to clear Plasmodium falciparum from the blood, and fast. But the big question remains: is it safe for mothers-to-be or for newborns exposed through breastfeeding?
Early on, few studies looked at pregnant women as research subjects. That made the early advice cautious, sometimes even inconsistent from country to country. Over recent years, researchers dug into this question and looked at the experiences of thousands of expectant mothers.
Studies now show artemether-lumefantrine in the second and third trimesters generally doesn’t increase the chance of birth defects or complications compared to known alternatives. The World Health Organization even backs this combination for treating malaria after the first trimester. In the first trimester, many doctors rely more on older medicines like quinine because artemisinins in early pregnancy produce a few safety concerns, even though real evidence of harm in humans is very thin.
After birth, mothers with malaria must keep breastfeeding if they can, to give babies a solid start in life. It makes sense to ask whether a drug like lumefantrine will end up in breast milk or harm a newborn. Researchers checked the concentration of lumefantrine in breast milk and found it only entered at tiny amounts. While data isn’t perfect, most work suggests no sign of harm to infants whose mothers took recommended doses. Doctors in clinics, faced with a bad malaria case, count on this evidence and usually advise mothers to keep breastfeeding while treated.
Clinics in malaria regions don’t have the luxury of perfect options. I remember patients walking for hours through mud for care. For them, fast, effective drugs often count for more than textbook risk tables. Lumefantrine, when paired with artemether, clears infection quickly, letting sick mothers go home, rest, and start healing. Not treating could mean more sickness, more deaths, and more hardship for families already stretched thin.
The evidence tilts toward safety in later pregnancy and while breastfeeding, but better studies could remove lingering doubts, especially for women in early pregnancy. Better tracking could help too—if doctors and nurses had systems to flag problems or side effects in real time, everyone would be safer. Access to rapid tests and skilled health workers makes all the difference in getting the right care fast.
Misunderstandings and rumors about medicine run wild where healthcare isn’t strong. People trust a local nurse or a neighbor. In my own family, simple explanations often worked better than scare stories, even when some skepticism lingered. Clinicians have to guide families, weighing risks with local context in mind. They need up-to-date, honest information and support from the health system to help women make informed choices.
Clear answers matter because real lives depend on them. Lumefantrine stands as a strong weapon against malaria for many pregnant or breastfeeding women across the world, especially where the threat of malaria is constant and dangerous.
Lumefantrine forms half of a powerful weapon against malaria, paired with artemether in a combination that shows up in clinics all over regions hit hardest by the disease. Doctors like to use this combo because of its track record in clearing parasites. Despite this, patients don’t just walk around with malaria — they also take medicines for all sorts of other illnesses, sometimes all at once. That’s where real life gets messy, and the worry about drug interactions steps in.
Inside the body, a group of liver enzymes called CYP450 handles a lot of drug clean-up duties. Lumefantrine leans heavily on an enzyme called CYP3A4 for its breakdown. This point turns crucial when you toss in other drugs that demand the same enzyme or mess with its activity.
Take some antibiotics, heart medicines, antifungals, or even some food like grapefruit juice: they don’t just keep to themselves. By pushing CYP3A4 into overdrive or slowing it down, these drugs either clear lumefantrine too fast, weakening its malaria-fighting punch, or let it build up, spiking the chance of side effects.
Clinics in busy, low-resource areas sometimes lack tools to check for these interactions. Patients fill their pill boxes with whatever the family has at home, leading to a dangerous mix. Healthcare staff juggle dozens of cases each day. The margin for error narrows. That’s why clear records, honest doctor-patient conversations, and pharmacy follow-up matter more than ever, especially in places where malaria, HIV, and chronic conditions cross paths.
Doctors and pharmacists need training that goes beyond textbooks. Local knowledge about frequently used medicines helps spot the most likely trouble spots for interactions. Digital apps that flag potential problems can save lives in busy clinics. More awareness among patients, from posters in waiting rooms to conversations at the pharmacy window, puts some safety back in their hands. Checking for herbal remedies or over-the-counter drugs that slip under the radar pulls another layer into view.
Malaria control won’t stand still on drug treatments. Combination pills keep evolving, and so do the realities of what people actually take or can access. Keeping up with these changes, adjusting practices, and sharing new information openly makes all the difference for real people in high-risk communities.
| Names | |
| Preferred IUPAC name | 2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-(4-chlorobenzylidene)-9H-fluoren-4-yl]ethanol |
| Other names |
Benflumetol Benflumetolum CGP 56697 LUM Riamet (in combination with artemether) |
| Pronunciation | /luː.məˈfæn.trɪn/ |
| Identifiers | |
| CAS Number | 82186-77-4 |
| Beilstein Reference | Beilstein Reference: 6742633 |
| ChEBI | CHEBI:65310 |
| ChEMBL | CHEMBL480 |
| ChemSpider | 215104 |
| DrugBank | DB06708 |
| ECHA InfoCard | 03c0ae653b-30ef-4063-a4d3-df4cc866e7b2 |
| EC Number | EC 617-626-5 |
| Gmelin Reference | 89206 |
| KEGG | D08120 |
| MeSH | Dichlorobenzenes |
| PubChem CID | 60733 |
| RTECS number | LU7850000 |
| UNII | 6L6H21E5B8 |
| UN number | UN3077 |
| Properties | |
| Chemical formula | C30H32Cl3NO |
| Molar mass | 528.95 g/mol |
| Appearance | A yellow crystalline powder |
| Odor | Odorless |
| Density | 1.19 g/cm3 |
| Solubility in water | Practically insoluble in water |
| log P | 5.6 |
| Vapor pressure | 4.97E-14 mmHg at 25°C |
| Acidity (pKa) | 8.74 |
| Basicity (pKb) | 8.74 |
| Magnetic susceptibility (χ) | -81.0 × 10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.782 |
| Viscosity | Viscosity: 0.417 Pa·s |
| Dipole moment | 4.94 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 365.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -276.7 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -6594 kJ/mol |
| Pharmacology | |
| ATC code | P01BF01 |
| Hazards | |
| Main hazards | May cause eye, skin, and respiratory tract irritation. Harmful if swallowed. |
| GHS labelling | GHS labelling of Lumefantrine: `"Warning; H302; H315; H319; H335"` |
| Pictograms | antiinfectives|antiparasitic_agents|antimalarials |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. |
| Precautionary statements | P264, P270, P273, P301+P312, P330, P501 |
| NFPA 704 (fire diamond) | 1-2-0-0 |
| Flash point | 120°C |
| Autoignition temperature | Autoignition temperature: 400°C |
| Lethal dose or concentration | LD50 (rat, oral): >2,000 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Lumefantrine: "2,800 mg/kg (rat, oral) |
| PEL (Permissible) | Not established |
| REL (Recommended) | 1200 mg |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Halofantrine Quinidine Quinine Mefloquine Chloroquine |
